Intraperitoneal photodynamic therapy for peritoneal metastasis of epithelial ovarian cancer. Limits and future prospects

被引:8
作者
Azais, H. [1 ,2 ]
Mordon, S. [2 ]
Collinet, P. [2 ,3 ]
机构
[1] Hop Univ Pitie Salpetriere Charles Foix, AP HP, Serv Chirurg & Cancerol Gynecol & Mammaire, Blvd Hop, F-75013 Paris, France
[2] CHU Lille, INSERM, ONCO THAI Image Assisted Laser Therapy Oncol U118, F-59000 Lille, France
[3] CHRU Lille, Serv Gynecol Medicochirurg, F-59000 Lille, France
来源
GYNECOLOGIE OBSTETRIQUE FERTILITE & SENOLOGIE | 2017年 / 45卷 / 04期
关键词
Photodynamic therapy; Ovarian cancer; Photosensitizer; Folate receptor; FOLATE RECEPTOR-ALPHA; PROTOPORPHYRIN-IX FLUORESCENCE; PHASE-II TRIAL; 5-AMINOLEVULINIC ACID; DEBULKING SURGERY; CYTOREDUCTIVE SURGERY; PHOTOFRIN UPTAKE; NORMAL-TISSUES; TUMOR; EXPRESSION;
D O I
10.1016/j.gofs.2017.02.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
High peritoneal recurrence rate in advanced epithelial ovarian cancer after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, raises the issue of peritoneal microscopic disease management and requires the development of additional locoregional treatment strategies. Photodynamic therapy is an effective treatment already applied in other medical and surgical indications. After administration of a photosensitizer which accumulates in cancer cells, illumination with a light of adequate wavelength may induce photochemical reaction between photosensitizer and tissue oxygen which lead to reactive oxygen species production and cytotoxic phenomenon. Photodynamic therapy's ability to treat superficial lesions disseminated on large area makes it an excellent candidate to insure destruction of microscopic peritoneal metastases in addition to macroscopic cytoreductive surgery in order to decrease peritoneal recurrence rate. Development of intraperitoneal photodynamic therapy has been limited by its poor tolerance related to the lack of specificity of photosensitizers and the location of the metastases in proximity to adjacent intraperitoneal organs. Our aim is to review clinical data concerning intraperitoneal photodynamic therapy and epithelial ovarian cancer to identify the limits of this strategy and to provide solutions which may be applied to solve these barriers and enable safe and effective treatment. Targeted photosensitizers and innovative illumination solutions are mandatory to continue research in this field and to consider the feasibility of clinical trials. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:249 / 256
页数:8
相关论文
共 65 条
  • [1] Photodynamic Therapy of Cancer: An Update
    Agostinis, Patrizia
    Berg, Kristian
    Cengel, Keith A.
    Foster, Thomas H.
    Girotti, Albert W.
    Gollnick, Sandra O.
    Hahn, Stephen M.
    Hamblin, Michael R.
    Juzeniene, Asta
    Kessel, David
    Korbelik, Mladen
    Moan, Johan
    Mroz, Pawel
    Nowis, Dominika
    Piette, Jacques
    Wilson, Brian C.
    Golab, Jakub
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2011, 61 (04) : 250 - 281
  • [2] Surgical cytoreduction for recurrent epithelial ovarian cancer
    Al Rawahi, Thuria
    Lopes, Alberto D.
    Bristow, Robert E.
    Bryant, Andrew
    Elattar, Ahmed
    Chattopadhyay, Supratik
    Galaal, Khadra
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [3] Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas
    Albanese, Alfonso M.
    Albanese, Eduardo F.
    Mino, Jorge H.
    Gomez, Elena
    Gomez, Marta
    Zandomeni, Marcos
    Merlo, Alicia B.
    [J]. SURGICAL AND RADIOLOGIC ANATOMY, 2009, 31 (05) : 369 - 377
  • [4] Intracellular signaling mechanisms in photodynamic therapy
    Almeida, RD
    Manadas, BJ
    Carvalho, AP
    Duarte, CB
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2004, 1704 (02): : 59 - 86
  • [5] Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy
    Ascencio, Manuel
    Collinet, Pierre
    Farine, M. O.
    Mordon, Serge
    [J]. LASERS IN SURGERY AND MEDICINE, 2008, 40 (05) : 332 - 341
  • [6] Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy
    Ascencio, Manuel
    Estevezac, Juan Pablo
    Delemer, Marie
    Farine, Marie Dile
    Collinet, Pierre
    Mordon, Serge
    [J]. PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2008, 5 (03) : 210 - 216
  • [7] Dealing with microscopic peritoneal metastases of epithelial ovarian cancer. A surgical challenge
    Azais, Henri
    Estevez, Juan Pablo
    Foucher, Perine
    Kerbage, Yohan
    Mordon, Serge
    Collinet, Pierre
    [J]. SURGICAL ONCOLOGY-OXFORD, 2017, 26 (01): : 46 - 52
  • [8] Targeted approaches and innovative illumination solutions: A new era for photodynamic therapy applications in gynecologic oncology?
    Azais, Henri
    Betrouni, Nacim
    Mordon, Serge
    Collinet, Pierre
    [J]. PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2016, 13 : 128 - 129
  • [9] Assessment of the specificity of a new folate-targeted photosensitizer for peritoneal metastasis of epithelial ovarian cancer to enable intraperitoneal photodynamic therapy. A preclinical study
    Azais, Henri
    Schmitt, Caroline
    Tardivel, Meryem
    Kerdraon, Olivier
    Stallivieri, Aurelie
    Frochot, Celine
    Betrouni, Nacim
    Collinet, Pierre
    Mordon, Serge
    [J]. PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2016, 13 : 130 - 138
  • [10] Fischer 344 Rat A Preclinical Model for Epithelial Ovarian Cancer Folate-Targeted Therapy
    Azais, Henri
    Queniat, Gurvan
    Bonner, Caroline
    Kerdraon, Olivier
    Tardivel, Meryem
    Jetpisbayeva, Gulim
    Frochot, Celine
    Betrouni, Nacim
    Collinet, Pierre
    Mordon, Serge
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (07) : 1194 - 1200